While the peak of the COVID-19 pandemic seems to have passed, the effects of post-COVID conditions on public health remain. A new study led by Weill Cornell Medicine and NewYork-Presbyterian investigators has found that the risk of long COVID and its symptoms present very differently across diverse populations and suggests that further investigation is needed to accurately define the disease and improve diagnosis and treatment.
A team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including omicron, the most recent.
A new preclinical study by Weill Cornell Medicine investigators found that certain bacteria in the gut may reduce susceptibility to SARS-CoV-2 infection, improve the immune response and prevent blood clots that can occur in severe COVID-19 illness.
Adult vaccination rates and social determinants of health—or the social and economic conditions in which families live and work—have played an important role in children’s mental health during the pandemic, according to a new study led by Weill Cornell Medicine investigators.
The SARS-CoV-2 virus can infect specialized pacemaker cells that maintain the heart’s rhythmic beat, setting off a self-destruction process within the cells, according to a preclinical study co-led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and NYU Grossman School of Medicine.
Booster doses of mRNA vaccines provided strong protection against hospitalization and death from COVID-19 in Qatar, though breakthrough SARS-CoV-2 infections were greater for the omicron variant compared with the delta variant, according to a study by investigators at Weill Cornell Medicine—Qatar.
Weill Cornell Medicine has been awarded a $9.8 million grant from the National Institutes of Health to lead a consortium of health care institutions that are analyzing nationwide health data in an effort to unravel the complexities of long COVID.
An FDA-approved drug that has been in clinical use for more than 70 years may protect against lung injury and the risk of blood clots in severe COVID-19 and other disorders that cause immune-mediated damage to the lungs.
COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.
A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research.
With in-person teaching in hospital and clinic settings suspended as the COVID-19 pandemic emerged, Weill Cornell Medical College swiftly designed innovative telehealth courses that enabled medical students to take part in remote patient care while also positioning them for post-pandemic careers with expanded digital healthcare options.